ADVM vs. ESPR, RGNX, TRML, MBX, ACB, TERN, FHTX, TSHA, CYRX, and ANNX
Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), Cryoport (CYRX), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.
Adverum Biotechnologies vs.
Esperion Therapeutics (NASDAQ:ESPR) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership.
Esperion Therapeutics received 256 more outperform votes than Adverum Biotechnologies when rated by MarketBeat users. Likewise, 70.15% of users gave Esperion Therapeutics an outperform vote while only 60.20% of users gave Adverum Biotechnologies an outperform vote.
47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by company insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Adverum Biotechnologies has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat Adverum Biotechnologies' return on equity.
Esperion Therapeutics presently has a consensus target price of $6.75, indicating a potential upside of 269.86%. Adverum Biotechnologies has a consensus target price of $27.83, indicating a potential upside of 606.43%. Given Adverum Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adverum Biotechnologies is more favorable than Esperion Therapeutics.
In the previous week, Esperion Therapeutics had 8 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 9 mentions for Esperion Therapeutics and 1 mentions for Adverum Biotechnologies. Adverum Biotechnologies' average media sentiment score of 0.34 beat Esperion Therapeutics' score of -0.31 indicating that Adverum Biotechnologies is being referred to more favorably in the news media.
Esperion Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Adverum Biotechnologies has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Summary
Adverum Biotechnologies beats Esperion Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Adverum Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adverum Biotechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:ADVM) was last updated on 2/22/2025 by MarketBeat.com Staff
